GlassScriptPhysician profile
Sagar Rakshit
NPI 1528419181
$1,693.03
in general payments reported to CMS, 2019-2025
35 companies · $674 in 2025
The $674 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $537 · 2024: $482 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612 · Education: $81.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.03 |
| Education | $81.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $144.17 | 2023-2025 | Carvykti, Darzalex, Talvey |
| Pfizer INC. | $137.78 | 2023-2025 | |
| Novocure INC. | $135.18 | 2025 | Optune Lua (Novottf-200t) |
| Astrazeneca Pharmaceuticals LP | $111.69 | 2023-2025 | Enhertu |
| Daiichi Sankyo INC. | $104.04 | 2023-2025 | Enhertu, Injectafer |
| Incyte Corporation | $85.01 | 2023-2025 | Jakafi, Niktimvo, Monjuvi |
| Eisai INC. | $84.86 | 2023-2025 | |
| Genentech USA, INC. | $79.39 | 2023-2025 | Lunsumio, Perjeta, Itovebi |
| Pharmaessentia USA Corporation | $70.65 | 2023-2025 | Besremi |
| Abbvie INC. | $62.65 | 2025 | |
| Aveo Pharmaceuticals, INC. | $55.00 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $53.97 | 2024-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $48.59 | 2023-2025 | |
| Tempus Ai, INC | $41.56 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.50 | 2024-2025 | Alunbrig |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $36.57 | 2023-2025 | |
| Lilly USA, LLC | $31.88 | 2024-2025 | Jaypirca, Verzenio |
| E.R. Squibb & Sons, L.L.C. | $31.37 | 2023-2025 | Opdivo, Reblozyl |
| Seagen INC. | $28.33 | 2023 | Padcev, Tukysa |
| Tersera Therapeutics LLC | $27.40 | 2023 | Xermelo |
| Exelixis INC. | $25.74 | 2023 | Cabometyx |
| Emd Serono, INC. | $25.16 | 2024 | |
| Blueprint Medicines Corporation | $22.22 | 2023 | Ayvakit |
| Geron Corporation | $20.98 | 2025 | Rytelo |
| Immunogen, INC. | $20.30 | 2023 | Elahere |
| Servier Pharmaceuticals LLC | $19.97 | 2023 | |
| Coherus Oncology, INC. | $19.71 | 2024 | |
| Array Biopharma INC | $17.99 | 2024 | Braftovi, Lorbrena, Mektovi |
| Genzyme Corporation | $17.56 | 2023 | |
| Celgene Corporation | $16.72 | 2023 | Pomalyst |
| Glaxosmithkline, LLC. | $16.61 | 2023 | Jemperli, Zejula |
| Sobi, INC | $16.49 | 2025 | |
| Recordati_rare_diseases_inc. | $15.98 | 2025 | Enjaymo |
| G1 Therapeutics, INC. | $13.13 | 2023 | Cosela |
| Gilead Sciences, INC. | $12.88 | 2023 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Rakshit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.